TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06959082: Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

Sponsor: VSPharmTech Co.,Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$13,721,400

Rescue Site Savings

+$9,055,200

Unlock Full NCT06959082 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06959082 Rescue Dossier →